Nanobody Screening Services
Antibody Discovery Services
Nanobody Screening Overview
In camelid animals, a unique type of heavy chain antibody naturally lacks both a light chain and a CH1 domain in the heavy chain. The variable region (VHH) of this heavy chain possesses complete binding capabilities, allowing it to independently bind to antigens. These remarkable antibodies are commonly known as nanobodies.
Leveraging our state-of-the-art flow cytometry sorting platform and the previously developed HC mouse model, our company is adept at providing swift and comprehensive nanobody screening services. Our platform encompasses every step of the process, from animal immunization and single B cell screening to sequence analysis and antibody expression. We offer a one-stop solution for nanobody screening, ensuring a seamless and efficient experience for our clients.
In camelid animals, a unique type of heavy chain antibody naturally lacks both a light chain and a CH1 domain in the heavy chain. The variable region (VHH) of this heavy chain possesses complete binding capabilities, allowing it to independently bind to antigens. These remarkable antibodies are commonly known as nanobodies.
All Antibody Discovery Services
Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.
Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.
Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.
